Success Metrics

Clinical Success Rate
71.4%

Based on 30 completed trials

Completion Rate
71%(30/42)
Active Trials
9(16%)
Results Posted
107%(32 trials)
Terminated
12(22%)

Phase Distribution

Ph phase_3
7
13%
Ph phase_1
20
36%
Ph early_phase_1
1
2%
Ph phase_2
26
47%

Phase Distribution

21

Early Stage

26

Mid Stage

7

Late Stage

Phase Distribution54 total trials
Early Phase 1First-in-human
1(1.9%)
Phase 1Safety & dosage
20(37.0%)
Phase 2Efficacy & side effects
26(48.1%)
Phase 3Large-scale testing
7(13.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

69.8%

30 of 43 finished

Non-Completion Rate

30.2%

13 ended early

Currently Active

9

trials recruiting

Total Trials

55

all time

Status Distribution
Active(9)
Completed(30)
Terminated(13)
Other(3)

Detailed Status

Completed30
Terminated12
Active, not recruiting7
unknown3
Recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
55
Active
9
Success Rate
71.4%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (1.9%)
Phase 120 (37.0%)
Phase 226 (48.1%)
Phase 37 (13.0%)

Trials by Status

withdrawn12%
recruiting24%
active_not_recruiting713%
terminated1222%
unknown35%
completed3055%

Recent Activity

Clinical Trials (55)

Showing 20 of 55 trialsScroll for more
NCT03768063Phase 3

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Active Not Recruiting
NCT03694262Phase 2

The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

Completed
NCT02873962Phase 2

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Active Not Recruiting
NCT03899155Phase 2

Pan Tumor Rollover Study

Recruiting
NCT03617679Phase 2

Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

Completed
NCT04539327

Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study

Completed
NCT03559049Phase 1

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Terminated
NCT03338790Phase 2

An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Completed
NCT03542175Phase 1

A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy

Completed
NCT04276376Phase 2

Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

Terminated
NCT04624178Phase 2

A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma

Active Not Recruiting
NCT02711137Phase 1

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Terminated
NCT02975934Phase 3

A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Completed
NCT03522246Phase 3

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Active Not Recruiting
NCT03442556Phase 2

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Terminated
NCT02678182Phase 2

Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Active Not Recruiting
NCT03639935Phase 2

Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

Completed
NCT03845296Phase 2

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Completed
NCT04253262Phase 1

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Active Not Recruiting
NCT04209595Phase 1

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

Completed

Drug Details

Intervention Type
DRUG
Total Trials
55